The Telix Pharmaceuticals Ltd (ASX: TLX) share price is in focus today following the company’s Q3 2026 results, which saw group revenue grow 19% year on year to US$245 million, with Precision Medicine revenue jumping 30% to US$201 million.
What did Telix Pharmaceuticals report?
- Group revenue rose 19% versus Q3 2025 to US$245 million.
- Precision Medicine revenue increased 30% to US$201 million, driven by Illuccix and Gozellix.
- FDA approved Pixclara for glioma imaging; first U.S. commercial doses administered in September 2026.
- BiPASS Phase 3 prostate cancer study completed enrolment; FDA granted Fast Track Designation.
- Merger with Isotope Technologies Munich SE (ITM) announced, boosting therapeutics pipeline and isotope supply.
- FY 2026 revenue and other income expected to exceed US$1 billion.
What else do investors need to know?
Telix continues to expand its product pipeline, advancing multiple late-stage trials in prostate, brain, and kidney cancer. The company said U.S. dose volumes for its key commercial products rose slightly despite seasonal impacts, with September sales underpinning confidence in further annual growth.
Telix has also strengthened its manufacturing and supply capabilities. Through its Telix Manufacturing Solutions unit, the company expanded its U.S. micro-pharmacy network and secured more contracts for its isotope production technology. Its collaboration with Ekalia is expected to secure priority isotope access for new alpha therapy products.
On the corporate front, shareholders will vote in December on the ITM merger, a US$1.65 billion deal designed to create a vertically integrated leader in radiopharmaceuticals. The board welcomed David Gill as Chair and Marcin Firek as Company Secretary, further bolstering the company’s governance and leadership credentials.
What did Telix Pharmaceuticals management say?
Dr. Christian Behrenbruch, Managing Director and Group CEO, commented:
Demand for both Gozellix and Illuccix remained strong during the quarter, with U.S. dose volumes increasing 1% quarter-over-quarter, in line with our expectations and reflecting expected summer seasonality. We are pleased by the strong September exit run rate, supporting our confidence in delivering over 25% Precision Medicine revenue growth in 2026. We achieved an important milestone with the FDA approval of Pixclara, expanding our commercial portfolio, establishing a presence in neuro-oncology and further diversifying our revenue base. During the quarter, we announced a transformative merger with ITM, creating a leading vertically integrated radiopharmaceutical company with one of the industry’s broadest therapeutic pipelines and expanded isotope production and global manufacturing capabilities. This is aligned with our long-term growth strategy reinforcing our ability to reliably serve patients at scale.
What’s next for Telix Pharmaceuticals?
Looking ahead, Telix expects FY 2026 revenue and other income to exceed US$1 billion, thanks to continued growth in its Precision Medicine business and increased commercial momentum from newly approved products. Revenue guidance factors in anticipated sales from Pixclara, a full-year contribution from RLS, and growth in key markets.
R&D spending guidance for the year was narrowed to US$240–260 million. The company’s development pipeline remains active, with trial results and regulatory milestones upcoming across its oncology portfolio, including a planned FDA resubmission for Zircaix and an expansion of Pixclara’s label. Integration planning for the ITM merger is also underway, aiming to boost Telix’s competitive position in targeted therapies.
Telix Pharmaceuticals share price snapshot
Over the past 12 months, Telix shares have declined 7%, trailing the S&P/ASX 200 Index (ASX: XJO), which has declined 3% over the same period.
The post Telix Pharmaceuticals Q3 2026 earnings: revenue up, pipeline advances appeared first on The Motley Fool Australia.
Wondering where to invest $1,000 right now?
When investing expert Scott Phillips has a stock tip, it can pay to listen. After all, the flagship Motley Fool Share Advisor newsletter he has run for over ten years has provided thousands of paying members with stock picks that have doubled, tripled or even more.*
Scott just revealed what he believes could be the ‘five best ASX stocks’ for investors to buy right now. We believe these stocks are trading at attractive prices and Scott thinks they could be great buys right now…
* Returns as of 6 March 2025
More reading
- Here are the top 10 ASX 200 shares today
- Telix vs Clinuvel Pharmaceuticals: Which ASX healthcare share deserves your next $1,000 of investment capital?
- UBS thinks Telix Pharmaceuticals shares will go how high?
- Here are the top 10 ASX 200 shares today
- Telix Pharmaceuticals wins FDA Fast Track for BiPASS prostate cancer imaging
Motley Fool contributor Laura Stewart has no position in any of the stocks mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has positions in and has recommended Telix Pharmaceuticals. The Motley Fool Australia has recommended Telix Pharmaceuticals. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips. This article was prepared with the assistance of Large Language Model (LLM) tools for the initial summary of the company announcement. Any content assisted by AI is subject to our robust human-in-the-loop quality control framework, involving thorough review, substantial editing, and fact-checking by our experienced writers and editors holding appropriate credentials. The Motley Fool Australia stands behind the work of our editorial team and takes ultimate responsibility for the content published by The Motley Fool Australia.